Türkiye vs Vanuatu: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Türkiye
0.0%
in 2024
Vanuatu
1.8%
in 2024
Türkiye rank
13th
Vanuatu rank
14th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Türkiye
- Vanuatu
How they compare
Vanuatu currently reports 1.8% against 0.0% in Türkiye, a difference of 1.8%.
Across all 10 years both countries report, Vanuatu has been ahead every year.
Türkiye ranks 13th and Vanuatu ranks 14th of 15 countries.
Vanuatu has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Türkiye | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 1.6% | 1.5% | Vanuatu |
| 2020s | 0.1% | 1.7% | 1.6% | Vanuatu |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Türkiye or Vanuatu?
- Vanuatu, at 1.8% against 0.0% in Türkiye as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Türkiye and Vanuatu?
- 1.8%, with Vanuatu ahead.
- How many years of comparable data are there for Türkiye and Vanuatu?
- 10 years are reported by both, from 2015 to 2024.
- How do Türkiye and Vanuatu rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Türkiye ranks 13th and Vanuatu ranks 14th of 15 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.